Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low - Here's What Happened

Sysmex logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Sysmex ADR hit a new 52-week low of $8.15 on Tuesday, trading about 294,823 shares and down from a prior close of $8.69.
  • Citigroup downgraded Sysmex from "strong-buy" to "hold" on March 16, and the consensus rating is currently a Hold (one Buy, two Holds).
  • Recent results showed an EPS of $0.15 beating estimates by $0.01 and revenue of $837.3M topping forecasts; the company has a market cap of about $5.13B and a P/E near 17.
  • MarketBeat previews the top five stocks to own by June 1st.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as $8.15 and last traded at $8.15, with a volume of 294823 shares trading hands. The stock had previously closed at $8.69.

Analyst Upgrades and Downgrades

Separately, Citigroup lowered Sysmex from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold".

Get Our Latest Research Report on SSMXY

Sysmex Price Performance

The company has a market capitalization of $5.13 billion, a price-to-earnings ratio of 16.98 and a beta of 1.13. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33. The business has a 50 day moving average price of $8.82 and a 200-day moving average price of $9.67.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The company had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. Research analysts predict that Sysmex Corporation ADR will post 0.44 EPS for the current fiscal year.

Sysmex Company Profile

(Get Free Report)

Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sysmex Right Now?

Before you consider Sysmex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.

While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines